• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SORIN GROUP ITALIA S.R.L. PERCEVAL SUTURELESS AORTIC HEART VALVE; TISSUE HEART VALVES

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SORIN GROUP ITALIA S.R.L. PERCEVAL SUTURELESS AORTIC HEART VALVE; TISSUE HEART VALVES Back to Search Results
Model Number PVS25
Device Problem Patient-Device Incompatibility (2682)
Patient Problem Complete Heart Block (2627)
Event Date 10/15/2019
Event Type  Injury  
Event Description
The manufacturer was informed on this event through the sure avr registry.On (b)(6) 2019, a patient received a perceval pvs25 in aortic position.No concomitant procedures were performed.The patient received a permanent pacemaker on 15 oct 2019 due to an atrio-ventricular block grade iii, indicated as a new conduction abnormality.The patient was discharged on (b)(6) 2019 with a good device functionality (no central/perivalvular leaks, mean gradient 14mmhg).No adverse events are reported in the database for this patient.
 
Manufacturer Narrative
A complete manufacturing and material records review for the device (model: pvs25, sn: (b)(6)) has been performed.The results confirmed that the device satisfied all material, visual and performance standards required at the time of manufacture and release.Since the device was not explanted, no further investigation can be performed at this time.Based on the available information, the root cause of the event reported cannot be definitively stated.However, based on the documents review performed, no manufacturing deficits were identified.Conduction disorders are common in patients with aortic valve diseases.As a result, it is common for patients to receive permanent pacemaker implantation after aortic valve replacement.Risk factors include preexisting conducting disease and preoperative aortic regurgitation.This event is, therefore, a known, inherent risk of the procedure, and it is listed among the potential adverse events in the perceval ifu.
 
Manufacturer Narrative
Livanova is providing a corrected section e.Upon notification, this event was mistakenly associated with the wrong healthcare facility information due to a clerical error.This information has now been corrected in this report.Livanova would like to clarify that the reporting activity is not otherwise impacted by this corrected information, as the description of the event, investigation performed, and root cause analysis remain unchanged as a result of the discrepancy noted.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PERCEVAL SUTURELESS AORTIC HEART VALVE
Type of Device
TISSUE HEART VALVES
Manufacturer (Section D)
SORIN GROUP ITALIA S.R.L.
strada crescentino snc
saluggia, vercelli
MDR Report Key9386349
MDR Text Key168621558
Report Number1718850-2019-01182
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Distributor
Type of Report Initial,Followup,Followup
Report Date 10/30/2019,05/25/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date06/27/2023
Device Model NumberPVS25
Device Catalogue NumberICV1210
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Distributor Facility Aware Date10/30/2019
Device Age4 MO
Event Location Hospital
Date Report to Manufacturer10/30/2019
Initial Date Manufacturer Received Not provided
Initial Date FDA Received11/27/2019
Supplement Dates Manufacturer Received10/30/2019
10/30/2019
Supplement Dates FDA Received12/12/2019
05/25/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age79 YR
Patient Weight69
-
-